Pancreatic Cancer Today
Overview
Affiliations
Carcinoma of the exocrine pancreas remains a challenging disease with poor prognosis mainly due to advanced stage by the time of presentation, the early systemic dissemination and its extraordinary local tumor progression. Surgery has little more to offer in improvement of curative percentage of disease and some progress has been made in the medical management of pancreatic cancer with the introduction and use of new chemical agents and with combined immunochemotherapy and chemoradiotherapy. The purpose of this review article is to focus on all recent advances in the management of pancreatic cancer. We review the current trial literature emphasizing the risk factors, the molecular biology of the tumor, and the therapeutic approach.
Zhang P, Guo Z, Hu R, He X, Jiao X, Zhu X Tumour Biol. 2015; 36(12):9693-701.
PMID: 26152285 DOI: 10.1007/s13277-015-3704-8.
Nanodelivery of Parthenolide Using Functionalized Nanographene Enhances its Anticancer Activity.
Karmakar A, Xu Y, Mustafa T, Kannarpady G, Bratton S, Radominska-Pandya A RSC Adv. 2015; 5(4):2411-2420.
PMID: 25574376 PMC: 4283950. DOI: 10.1039/c4ra10871j.
Saeed L, Mahmood M, Pyrek S, Fahmi T, Xu Y, Mustafa T J Appl Toxicol. 2014; 34(11):1188-99.
PMID: 25220893 PMC: 4416215. DOI: 10.1002/jat.3018.
Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro.
Liu J, Cai M, Xin Y, Wu Q, Ma J, Yang P J Exp Clin Cancer Res. 2010; 29:108.
PMID: 20698986 PMC: 2924280. DOI: 10.1186/1756-9966-29-108.
Cousin B, Ravet E, Poglio S, De Toni F, Bertuzzi M, Lulka H PLoS One. 2009; 4(7):e6278.
PMID: 19609435 PMC: 2707007. DOI: 10.1371/journal.pone.0006278.